Suresh Senan, MRCP, FRCR, PhD, discusses the significance of the FDA approval of durvalumab for patients with limited-stage small cell lung cancer.
Suresh Senan, MRCP, FRCR, PhD
Advertisement
Articles by Suresh Senan, MRCP, FRCR, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
2
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
Dr Gangat on Phase 2 Efficacy and Safety Data for DISC-3405 in Polycythemia Vera
5